JP5656408B2 - 心臓の神経支配を画像化するためのリガンド - Google Patents

心臓の神経支配を画像化するためのリガンド Download PDF

Info

Publication number
JP5656408B2
JP5656408B2 JP2009544215A JP2009544215A JP5656408B2 JP 5656408 B2 JP5656408 B2 JP 5656408B2 JP 2009544215 A JP2009544215 A JP 2009544215A JP 2009544215 A JP2009544215 A JP 2009544215A JP 5656408 B2 JP5656408 B2 JP 5656408B2
Authority
JP
Japan
Prior art keywords
mmol
nmr
mhz
added
dmso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009544215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514786A (ja
JP2010514786A5 (enExample
Inventor
アジャイ・プロイト
トーマス・ディ・ハリス
ハイケ・エス・ラデケ
サイモン・ピー・ロビンソン
ミン・ユ
デイビッド・エス・カセビアー
マイケル・ティ・アズール
Original Assignee
ランセウス メディカル イメージング， インコーポレイテッド
ランセウス メディカル イメージング， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ランセウス メディカル イメージング， インコーポレイテッド, ランセウス メディカル イメージング， インコーポレイテッド filed Critical ランセウス メディカル イメージング， インコーポレイテッド
Publication of JP2010514786A publication Critical patent/JP2010514786A/ja
Publication of JP2010514786A5 publication Critical patent/JP2010514786A5/ja
Application granted granted Critical
Publication of JP5656408B2 publication Critical patent/JP5656408B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/70—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/06—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2009544215A 2006-12-26 2007-12-21 心臓の神経支配を画像化するためのリガンド Active JP5656408B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87721106P 2006-12-26 2006-12-26
US60/877,211 2006-12-26
PCT/US2007/088500 WO2008083056A2 (en) 2006-12-26 2007-12-21 Ligands for imaging cardiac innervation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014152244A Division JP6021860B2 (ja) 2006-12-26 2014-07-25 心臓の神経支配を画像化するためのリガンド

Publications (3)

Publication Number Publication Date
JP2010514786A JP2010514786A (ja) 2010-05-06
JP2010514786A5 JP2010514786A5 (enExample) 2011-02-24
JP5656408B2 true JP5656408B2 (ja) 2015-01-21

Family

ID=39307501

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009544215A Active JP5656408B2 (ja) 2006-12-26 2007-12-21 心臓の神経支配を画像化するためのリガンド
JP2014152244A Active JP6021860B2 (ja) 2006-12-26 2014-07-25 心臓の神経支配を画像化するためのリガンド
JP2016085372A Pending JP2016183164A (ja) 2006-12-26 2016-04-21 心臓の神経支配を画像化するためのリガンド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014152244A Active JP6021860B2 (ja) 2006-12-26 2014-07-25 心臓の神経支配を画像化するためのリガンド
JP2016085372A Pending JP2016183164A (ja) 2006-12-26 2016-04-21 心臓の神経支配を画像化するためのリガンド

Country Status (20)

Country Link
US (5) US8491868B2 (enExample)
EP (5) EP2114873B1 (enExample)
JP (3) JP5656408B2 (enExample)
KR (4) KR20170102580A (enExample)
CN (3) CN101687780B (enExample)
AU (1) AU2007339954B2 (enExample)
BR (1) BRPI0722082A8 (enExample)
CA (2) CA2984226C (enExample)
CO (1) CO6231002A2 (enExample)
DK (3) DK2474525T3 (enExample)
ES (3) ES2805286T3 (enExample)
IL (3) IL199563A (enExample)
MX (2) MX2009007018A (enExample)
PL (1) PL2114873T3 (enExample)
PT (1) PT2114873E (enExample)
RU (1) RU2506256C2 (enExample)
SG (1) SG177918A1 (enExample)
TW (2) TWI549692B (enExample)
WO (1) WO2008083056A2 (enExample)
ZA (1) ZA200904828B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016183164A (ja) * 2006-12-26 2016-10-20 ランセウス メディカル イメージング， インコーポレイテッド 心臓の神経支配を画像化するためのリガンド

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US8936777B2 (en) 2010-02-08 2015-01-20 Lantheus Medical Imaging, Inc. Methods and apparatus for synthesizing imaging agents, and intermediates thereof
WO2011143360A2 (en) * 2010-05-11 2011-11-17 Lantheus Medical Imaging, Inc. Compositions, methods and systems for the synthesis and use of imaging agents
MX354217B (es) * 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
MX362384B (es) 2010-05-14 2019-01-15 Dana Farber Cancer Inst Inc Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
AR086113A1 (es) 2011-04-30 2013-11-20 Abbott Lab Isoxazolinas como agentes terapeuticos
EP2753605B1 (en) 2011-09-09 2019-03-27 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
CA2869398C (en) 2012-04-10 2019-10-22 Lantheus Medical Imaging, Inc. Radiopharmaceutical synthesis methods
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
WO2014052454A1 (en) * 2012-09-25 2014-04-03 The Regents Of The University Of Michigan Imaging agents
EP2948188B1 (en) * 2013-01-24 2021-09-08 Tylerton International Holdings Inc. Neuronal imaging and treatment
WO2014115151A1 (en) * 2013-01-24 2014-07-31 Tylerton International Holdings Inc. Body structure imaging
WO2014141247A1 (en) * 2013-03-11 2014-09-18 Tylerton International Holdings Inc. Modeling the autonomous nervous system and uses thereof
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
US10052495B2 (en) 2013-09-08 2018-08-21 Tylerton International Inc. Detection of reduced-control cardiac zones
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CN106102583B (zh) 2014-01-10 2024-08-09 泰勒顿国际控股公司 瘢痕和纤维心脏区的检测
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
EP3174466B1 (en) 2014-07-30 2020-06-17 Navix International Limited Probe localization
BR112017002190A2 (pt) 2014-08-08 2017-11-21 Dana Farber Cancer Inst Inc derivados de di-hidropteridinona e usos dos mesmos
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US10881668B2 (en) 2015-09-11 2021-01-05 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
CN107892651A (zh) * 2017-11-29 2018-04-10 陕西慧康生物科技有限责任公司 一种合成dl‑盐酸麻黄碱的方法
EP3866692B1 (en) * 2018-10-15 2025-07-23 Bristol-Myers Squibb Company Radioligands for imaging the lpa1 receptor
EP3682906A1 (en) 2019-01-17 2020-07-22 Julius-Maximilians-Universität Würzburg Compound targeting norepinephrine transporter
CN109748825B (zh) * 2019-02-01 2022-02-18 原子高科股份有限公司 一种18f标记的胍甲基取代苯类似物及其应用
KR102690858B1 (ko) 2020-07-14 2024-08-02 한국과학기술원 이산화탄소와 개미산만으로 성장 가능한 재조합 미생물 및 상기 재조합 미생물을 이용하여 유용물질을 제조하는 방법

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6012A (en) * 1849-01-09 Lithographing co
FR1010218A (fr) 1949-02-10 1952-06-09 American Cyanamid Co Perfectionnements aux sels de guanidine
GB1215255A (en) 1968-03-13 1970-12-09 Pfizer & Co C Halophenylalkylguanidine compounds
US4094881A (en) 1976-03-10 1978-06-13 Smithkline Corporation Process for preparing triazolethiols
US4275074A (en) 1979-03-09 1981-06-23 Graham J. Dobbie Catecholamine treatment of ocular hypertension
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4258188A (en) * 1980-02-04 1981-03-24 American Home Products Corporation 2-(1-Piperazinyl)-cycloheptimidazole derivatives
US4622217A (en) * 1984-04-27 1986-11-11 The Regents Of The University Of Michigan I-4-amino-3-iodobenzylguanidine as imaging and therapeutic agent
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
AU1503888A (en) * 1987-04-24 1988-10-27 King Faisal Specialist Hospital & Research Centre Method of producing iodine124 and meta-iodobenzlyguanidine containing iodine124
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5663166A (en) * 1991-10-18 1997-09-02 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
TW279864B (enExample) * 1993-02-19 1996-07-01 Janssen Pharmaceutica Nv
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
EP0639573A1 (de) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
AU703340B2 (en) 1995-06-26 1999-03-25 Chelator Llc Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy and diagnosis
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
JP2001527527A (ja) 1996-11-27 2001-12-25 デュポン ファーマシューティカルズ カンパニー 新規インテグリン受容体拮抗薬
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
WO1999018053A1 (en) 1997-10-02 1999-04-15 The University Of Western Ontario Preparation of radiolabelled haloaromatics via polymer-bound intermediates
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
AU3406599A (en) 1998-04-09 1999-11-01 Institut Fur Diagnostikforschung Gmbh An Der Freien Universitat Berlin Novel benzyl guanidine derivatives for therapy and (in-vivo) and (in-vitro) diagnosis
WO2000009115A1 (en) 1998-08-14 2000-02-24 Smithkline Beecham Corporation Grp receptor ligands
EP1140204A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
DE10114561A1 (de) 2001-03-24 2002-09-26 Wella Ag Verwendung von Mitteln enthaltend Kreatin, Kreatin und/oder deren Derivaten zur Verstärkung und Strukturverbesserung von keratinischen Fasern
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
WO2004018465A2 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Benzonaphthyridines with pde 3/4 inhibiting activity
WO2004037166A2 (en) 2002-09-17 2004-05-06 Isis Pharmaceuticals, Inc. Therapeutic guanidines
US7754188B2 (en) * 2003-06-30 2010-07-13 Merck Sharp & Dohme Corp. Radiolabeled cannabinoid-1 receptor modulators
EP1691777A4 (en) * 2003-12-01 2010-10-13 Medi Physics Inc NEW DIFFERENTIAL IMAGING METHOD
WO2005095345A2 (en) * 2004-03-23 2005-10-13 Achillion Pharmaceuticals, Inc. Heteroaryl guanidines as inhibitors of viral replication
US9388122B2 (en) 2004-05-28 2016-07-12 Hamamatsu Photonics K.K. Radioactive tyrosine derivative, method for producing same, labeling agent for positron imaging and medical agent for assessing grade of malignancy of tumor respectively composed of radioactive tyrosine derivative, and method for detecting tumor
ATE493152T1 (de) 2004-09-23 2011-01-15 Guerbet Sa Liposomale kontrastmittel für die cest-bildgebung
US20060083681A1 (en) * 2004-10-18 2006-04-20 Ajay Purohit Compounds for myocardial perfusion imaging
US7534418B2 (en) * 2004-12-10 2009-05-19 The Regents Of The University Of Michigan Imaging agents
GB0512770D0 (en) 2005-06-23 2005-07-27 Hammersmith Imanet Ltd Imaging compounds
MX2009005920A (es) 2006-12-13 2009-06-16 Hoffmann La Roche Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina.
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
EP2114873B1 (en) * 2006-12-26 2013-02-20 Lantheus Medical Imaging, Inc. N-[3-bromo-4-(3- [18f]fluoropropoxy)-benzyl]-guanidine for imaging cardiac innervation
WO2008082305A1 (en) 2006-12-28 2008-07-10 Raufoss Technology As Control arm
WO2008115593A1 (en) 2007-03-21 2008-09-25 The University Of Montana 1-[(2'-substituted)-piperazin-1'-yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents
KR20100095528A (ko) 2007-10-18 2010-08-31 베링거 인겔하임 인터내셔날 게엠베하 디하이드로티에노[3,2-ｄ]피리미딘의 제조방법 및 상기 제조방법에서 사용된 중간체
WO2010015340A1 (en) 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
GB0906274D0 (en) 2009-04-09 2009-05-20 Ge Healthcare Ltd Imaging the central nervous system
CA2758883C (en) 2009-04-15 2020-03-10 Lantheus Medical Imaging, Inc. Stabilization of radiopharmaceutical compositions using ascorbic acid
CN101555232B (zh) 2009-05-21 2011-01-05 北京师范大学 氟-18标记哒嗪酮类化合物及制备方法和应用
JP5676600B2 (ja) 2009-07-08 2015-02-25 ランセウス メディカル イメージング， インコーポレイテッド 造影剤としてのｎ−アルコキシアミド抱合体
US8936777B2 (en) 2010-02-08 2015-01-20 Lantheus Medical Imaging, Inc. Methods and apparatus for synthesizing imaging agents, and intermediates thereof
WO2011143360A2 (en) 2010-05-11 2011-11-17 Lantheus Medical Imaging, Inc. Compositions, methods and systems for the synthesis and use of imaging agents
EP2753605B1 (en) 2011-09-09 2019-03-27 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP2671575A1 (en) 2012-06-04 2013-12-11 Universität Regensburg Ras inhibitors
JP2017131851A (ja) 2016-01-29 2017-08-03 日本特殊陶業株式会社 マイクロ波加熱用触媒材料、マイクロ波加熱用触媒体、及び、その製造方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016183164A (ja) * 2006-12-26 2016-10-20 ランセウス メディカル イメージング， インコーポレイテッド 心臓の神経支配を画像化するためのリガンド

Also Published As

Publication number Publication date
TW201628660A (zh) 2016-08-16
EP2474524A2 (en) 2012-07-11
EP2474524A3 (en) 2012-07-18
JP6021860B2 (ja) 2016-11-09
ZA200904828B (en) 2014-12-23
TWI549692B (zh) 2016-09-21
PT2114873E (pt) 2013-05-06
JP2014237679A (ja) 2014-12-18
ES2804801T3 (es) 2021-02-09
US10010631B2 (en) 2018-07-03
CA2673853A1 (en) 2008-07-10
CA2984226A1 (en) 2008-07-10
EP2114873A2 (en) 2009-11-11
AU2007339954A1 (en) 2008-07-10
US20250161500A1 (en) 2025-05-22
US20140030189A1 (en) 2014-01-30
HK1138260A1 (en) 2010-08-20
US11241509B2 (en) 2022-02-08
US12324845B2 (en) 2025-06-10
MX2009007018A (es) 2009-11-26
DK2474525T3 (da) 2020-07-13
CN101687780A (zh) 2010-03-31
TWI618544B (zh) 2018-03-21
CN105622463A (zh) 2016-06-01
KR20140140134A (ko) 2014-12-08
US20180339070A1 (en) 2018-11-29
WO2008083056A3 (en) 2009-04-30
JP2010514786A (ja) 2010-05-06
SG177918A1 (en) 2012-02-28
IL224396B (en) 2018-04-30
RU2009128591A (ru) 2011-02-10
KR101718160B1 (ko) 2017-03-20
AU2007339954B2 (en) 2013-06-20
EP2474525B1 (en) 2020-04-15
WO2008083056A2 (en) 2008-07-10
KR101810348B1 (ko) 2017-12-18
KR20160049044A (ko) 2016-05-04
CA2984226C (en) 2021-02-23
TW200848078A (en) 2008-12-16
EP2474525A2 (en) 2012-07-11
EP2474523A3 (en) 2012-07-18
EP2474523A2 (en) 2012-07-11
KR20090097946A (ko) 2009-09-16
CA2673853C (en) 2017-10-31
DK2114873T3 (da) 2013-05-13
BRPI0722082A2 (pt) 2014-04-01
MX367292B (es) 2019-08-13
CN110003079A (zh) 2019-07-12
ES2405655T3 (es) 2013-05-31
KR20170102580A (ko) 2017-09-11
PL2114873T3 (pl) 2013-08-30
CN105622463B (zh) 2019-02-22
CO6231002A2 (es) 2010-12-20
DK2474523T3 (da) 2020-07-13
CN101687780B (zh) 2016-01-20
EP2474525A3 (en) 2012-07-25
IL253885A0 (en) 2017-10-31
US20220288243A1 (en) 2022-09-15
US8491868B2 (en) 2013-07-23
BRPI0722082A8 (pt) 2018-03-13
RU2506256C2 (ru) 2014-02-10
EP2114873B1 (en) 2013-02-20
EP2474523B1 (en) 2020-04-08
JP2016183164A (ja) 2016-10-20
US20100221182A1 (en) 2010-09-02
EP2474526A2 (en) 2012-07-11
EP2474526A3 (en) 2012-07-25
ES2805286T3 (es) 2021-02-11
IL199563A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
JP6021860B2 (ja) 心臓の神経支配を画像化するためのリガンド
HK40011061A (en) Ligands for imaging cardiac innervation
HK1173429A (en) Ligands for imaging cardiac innervation
HK1138260B (en) N-[3-bromo-4-(3- [18f]fluoropropoxy)-benzyl]-guanidine for imaging cardiac innervation
HK1173430A (en) Ligands for imaging cardiac innervation
HK1173430B (en) Ligands for imaging cardiac innervation
HK1173429B (en) Ligands for imaging cardiac innervation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130520

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130718

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140725

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141125

R150 Certificate of patent or registration of utility model

Ref document number: 5656408

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250